Abiraterone-Induced Endocrinopathies-Reference-Cited by-同舟云学术

Abiraterone-Induced Endocrinopathies

Published:2023-02-17 Issue:2 Volume:1 Page:
ISSN:2755-1520
Container-title:JCEM Case Reports
language:en
Short-container-title:

Author:

Decamps Scarlett¹²,Lis Rita¹²,Ekanayake Preethika¹²^ORCID

Affiliation:

1. Division of Endocrinology, Diabetes and Metabolism, University of California , San Diego, 9350 Campus Point Drive, La Jolla, CA 92037 , USA

2. Department of Endocrinology, Diabetes and Metabolism, Veterans’ Affairs , 3350 La Jolla Village Drive, San Diego, CA 92161 , USA

Abstract

Abstract Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. However, little is documented in the endocrinology literature about the incidences of the endocrine side effects of abiraterone. In this case series, we discuss the diagnosis and management of 3 prostate cancer patients who experienced mineralocorticoid excess and secondary adrenal insufficiency related to abiraterone and prednisone use.

Publisher

The Endocrine Society

Link

https://academic.oup.com/jcemcr/article-pdf/1/2/luad039/51824901/luad039.pdf

Reference10 articles.

1. Phase 1 clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration resistant prostate cancer remains hormone driven;Attard;J Clin Oncol,2008

2. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

3. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomized, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019

4. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100;Richards;Cancer Res,2012

5. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic, castration-resistant prostate cancer, a randomized, open label, phase 2 study;Attard;JAMA Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone-Induced Secondary Hypertension: Two Wrongs Don’t Make a Right;Cureus;2024-05-14

2. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology;Current Opinion in Oncology;2024-02-26